Molecular Cloning, Heterologous Expression, Purification, and Evaluation of Protein–Ligand Interactions of CYP51 of ICandida krusei/I Azole-Resistant Fungal Strain

• Published in: Biomedicines Vol. 11; no. 11
• Main Authors: Tsybruk, Tatsiana V, Kaluzhskiy, Leonid A, Mezentsev, Yuri V, Makarieva, Tatyana N, Tabakmaher, Kseniya M, Ivanchina, Natalia V, Dmitrenok, Pavel S, Baranovsky, Alexander V, Gilep, Andrei A, Ivanov, Alexis S
• Format: Journal Article
• Language: English
• Published: MDPI AG 01-10-2023
• Subjects: Amino acids; Analysis; Antifungal agents; Care and treatment; Caspofungin; Cloning; Drug resistance in microorganisms; Fungi; Health aspects; Instrument industry; United Kingdom; Belarus; United States; Germany
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11112873

Due to the increasing prevalence of fungal diseases caused by fungi of the genus Candida and the development of pathogen resistance to available drugs, the need to find new effective antifungal agents has increased. Azole antifungals, which are inhibitors of sterol-14α-demethylase or CYP51, have been widely used in the treatment of fungal infections over the past two decades. Of special interest is the study of C. krusei CYP51, since this fungus exhibit resistance not only to azoles, but also to other antifungal drugs and there is no available information about the ligand-binding properties of CYP51 of this pathogen. We expressed recombinant C. krusei CYP51 in E. coli cells and obtained a highly purified protein. Application of the method of spectrophotometric titration allowed us to study the interaction of C. krusei CYP51 with various ligands. In the present work, the interaction of C. krusei CYP51 with azole inhibitors, and natural and synthesized steroid derivatives was evaluated. The obtained data indicate that the resistance of C. krusei to azoles is not due to the structural features of CYP51 of this microorganism, but rather to another mechanism. Promising ligands that demonstrated sufficiently strong binding in the micromolar range to C. krusei CYP51 were identified, including compounds 99 (Kd = 1.02 ± 0.14 µM) and Ch-4 (Kd = 6.95 ± 0.80 µM). The revealed structural features of the interaction of ligands with the active site of C. krusei CYP51 can be taken into account in the further development of new selective modulators of the activity of this enzyme.